Localization of antigen-presenting cells in Helicobacter pylori-infected gastric mucosa.
Helicobacter pylori (HP) infection is known to induce the specific immune response in the gastric mucosa. The immune response is triggered by presentation of antigen peptides on the major histocompatibility assembly of the antigen-presenting cells (APC) with the assistance of costimulatory molecules such as B7-1 (CD80) and B7-2 (CD86). Their counter-receptors or ligands on T cells are CD28 or cytotoxic lymphocyte-associated molecule-4. The aim of the present study was to clarify the localization of APC and their relation with T cells in HP-infected human gastric mucosa. Our findings suggest that the macrophages in the lamina propria may mainly act as APC in the HP-infected gastric mucosa, and the triggered immune response might be involved in the mucosal immune response in the inflamed gastric mucosa to invasive antigens related to HP organisms.
Suzuki
Tatsuhiko
T
Department of Gastroenterology, Sendai National Hospital and Department of Gastroenterology, Tohoku University School of Medicine, Sendai, Japan. ts@snh.go.jp
Kato
Katsuaki
K
Ohara
Shuichi
S
Noguchi
Kenji
K
Sekine
Hitoshi
H
Nagura
Hiroshi
H
Shimosegawa
Tooru
T
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D000938:Antigen-Presenting Cells / Q000276:immunology / Q000378:metabolism / Q000473:pathology*; D018106:CD28 Antigens / Q000032:analysis; D002452:Cell Count; D017291:Clarithromycin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D019084:Fluorescent Antibody Technique, Indirect; D005753:Gastric Mucosa / Q000276:immunology / Q000378:metabolism / Q000473:pathology*; D005756:Gastritis / Q000188:drug therapy / Q000382:microbiology / Q000473:pathology*; D006684:HLA-DR Antigens / Q000032:analysis; D016481:Helicobacter Infections / Q000276:immunology / Q000473:pathology*; D016480:Helicobacter pylori / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D007124:Immunoenzyme Techniques; D008264:Macrophages / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D008795:Metronidazole / Q000627:therapeutic use; D009853:Omeprazole / Q000627:therapeutic use; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D018106:CD28 Antigens; D006684:HLA-DR Antigens; D008795:Metronidazole; D017291:Clarithromycin; D009853:Omeprazole